MATRIX METALLOPROTEINASES 2 AND 9 IN AVOCATION OF MULTITUDINAL COMPLICATIONS IN EXPLICITLY TO CARCINOMA: REVIEW
DOI:
https://doi.org/10.22159/ajpcr.2017.v10i1.14214Abstract
Matrix metalloproteinases (MMPs) are a large group of calcium-dependent zinc containing endopeptidases which are mainly concerned with the remodeling of tissue along with degradation of the extracellular matrix. At the present scenario, there is knowledge of about 26 MMPs which are found to be highly regulated by the growth hormones, cytokines, etc., present within the body. At times of normal homeostasis, their levels within the body are low, and their number usually increases at times of pathological conditions. Its generation is known to occur from the pro-inflammatory cells and connective tissues. They may even lead to the process of apoptosis by its interactions with surface receptors. In the clinical trials sectors, various MMPs along with their inhibitors are examined to import the properties of being a high biomarker in the cancer diagnosis, antiangiogenic agents, various other disorders such as chronic allograft nephropathy, diabetic nephropathy, cardiovascular diseases, neuropathic pain, wound healing, angiogenesis processes, immune response, corneal ulceration, embryonic development, and nervous system disorders. As a result, enormous number of studies on this particular enzyme in the marking of cancer and their elevation in the above-mentioned diseases has to be carried out so that it would remain as a useful tool in their diagnosis. The present work is designed to emphasize the concise review of MMPs, in particularly MMP-2 and MMP-9 along with their variant roles, keeping in mind, that it would be advantageous for the researchers to bring out more promising results and to intensify diagnosis of various infirmities, especially in cancer.
Keywords: Matrix metalloproteinase-2, Matrix metalloproteinase-9, Biomarker, Matrix metalloproteinases, Carcinoma, Extracellular matrix, Malignancy, Gelatinases, Tumor.
Downloads
References
Varun BR, Nair BJ, Sivakumar TT, Joseph AP. Matrix metalloproteinases and their role in oral diseases: A review. Oral Maxillofac Pathol J 2012;3(1):0976-1225.
Sekhon BS. Matrix metalloproteinases – An overview. Res Rep Biol 2010;1:1-20.
Verma RP, Hansch C. Matrix metalloproteinases (MMPs): Chemical- biological functions and (Q) SARs. Sci Direct Bioorg Med Chem 2007;15(6):2223-68.
Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. Acute leukemia. Crit Rev Oncol Hematol 2004;50:87-100.
Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev 2006;25(1):115-36.
Hartung HP, Kieseier BC. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 2000;107:140-7.
Raffettoa JD, Khalilb RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008;75(2):346-59.
Outi K. Matrix Metalloproteinase-2 (Mmp-2) and -9 (Mmp-9) in Hematological Malignancies†Thesis Submitted On; 2003.
Kim JH, Kim JH, Cho CS, Jun HO, Kim DH, Yu YS, et al. Differential roles of matrix metalloproteinase-9 and -2, depending on proliferation or differentiation of retinoblastoma cells. Invest Ophthalmol Vis Sci 2010;51(3):1783-8.
Oguić R, MozetiÄ V, TeÅ¡ar EC, ÄŒupić DF, Mustać E, ÄorÄ‘ević G. Matrix metalloproteinases 2 and 9 immunoexpression in prostate carcinoma at the positive margin of radical prostatectomy specimens. Pathol Res Int 2014;2014:8.
Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002;94(1):17-25.
Hurst NG, Stocken DD, Wilson S, Keh C, Wakelam MJ, Ismail T. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer 2007;97(7):971-7.
Leeman MF, Curran S, Murray GI. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 2003;201(4):528-34.
Wagenaar-Miller RA, Gorden L, Matrisian LM. Matrix metalloproteinases in colorectal cancer: Is it worth talking about? Cancer Metastasis Rev 2004;23(1-2):119-35.
Gimeno-GarcÃa AZ, Santana-RodrÃguez A, Jiménez A, Parra-Blanco A, Nicolás-Pérez D, Paz-Cabrera C, et al. Up-regulation of gelatinases in the colorectal adenoma-carcinoma sequence. Eur J Cancer 2006;42(18):3246-52.
Walter L, Harper C, Garg P. Role of matrix metalloproteinases in inflammation/colitis-associated colon cancer. Immunogastroenterology 2003;2(1):22-8.
Määttä M, Soini Y, Liakka A, Autio-Harmainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane Type 1-MMP in hepatocellular and pancreatic adenocarcinoma: Implications for tumor progression and clinical prognosis. Clin Cancer Res 2000;6(7):2726-34.
Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25(1):9-34.
Talvensaari-Mattila A, Santala M, Soini Y, Turpeenniemi-Hujanen T. Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. Anticancer Res 2005;25(B):4101-6.
MareÄko I, Cvejić D, Å elemetjev S, PaskaÅ¡ S, Tatić S, Paunović I, et al. Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration. Croat Med J 2014;55(2):128-37.
Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;1(4):274-9.
Ahmad A, Sayed A, Ginnebaugh KR, Sharma V, Suri A, Saraph A, et al. Molecular docking and inhibition of matrix metalloproteinase-2 by novel difluorinatedbenzylidene curcumin analog. Am J Transl Res 2015;7(2):298-308.
Ngamenia B, Touaibia M, Belkaidc A, Ambassab P, Watchueng J, Patnam R, et al. Inhibition of matrix metalloproteinase-2 secretion by chalcones from the twigs of dorsteniabarteri bureau. ARKIVOC 2007;IX:91-103.
Kupferman ME, Fini ME, Muller WJ, Weber R, Cheng Y, Muschel RJ. Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression. Am J Pathol 2000;157(6):1777-83.
Liu RR, Li MD, Li T, Tan Y, Zhang M, Chen JC. Matrix metalloproteinase 2 (MMP2) protein expression and laryngeal cancer prognosis: A meta analysis. Int J Clin Exp Med 2015;8(2):2261-6.
Christopoulos TA, Papageorgakopoulou N, Theocharis DA, Aletras AJ, Tsiganos CP, Papadas TA, et al. Diagnostic and classification value of metalloproteinases in squamous human laryngeal carcinoma. Int J Oncol 2004;25(2):481-5.
Xu YM, Xie MQ, Liu T. The relationship between matrix metalloproteinases MMP-1 and MMP-2 with laryngeal cancer invasion and lymph node metastasis 2010;20:1930-4.
Wang XQ, Shan YC, Wang JQ. Matrix metalloproteinase 2 expression and clinical significance in laryngeal squamous cell carcinoma 2006;12:1109-10.
Lutgendorf SK, Lamkin DM, Jennings NB, Arevalo JM, Penedo F, DeGeest K, et al. Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin Cancer Res 2008;14(21):1-12.
Kanayama H. Matrix metalloproteinases and bladder cancer. J Med Invest 2001;48(1-2):31-43.
Weinrach DM, Wang KL, Wiley EL, Laskin WB. Immunohistochemical expression of matrix metalloproteinases 1, 2, 9, and 14 in dermatofibrosarcoma protuberans and common fibrous histiocytoma (dermatofibroma). Arch Pathol Lab Med 2004;12(8):1136-41.
OhnishiY,ItoY,TajimaS,IshibashiA,AraiK.Immunohistochemicalstudy of membrane type–matrix metalloproteinases (MT-MMPs) and matrix metalloproteinase-2 (MMP-2) in dermatofibroma and malignant fibrous histiocytoma. J Dermatol Sci 2002;28(2):119-25.
Macphee J, Stetson CR, Elwood BW, Patel K, McCallum J, Neto C, et al. Flavonol-enriched fraction from Vaccinium macrocarpon fruit
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
